Skip to main content

Cannabis Watch: Cannabis Stocks Mostly Higher After FDA Head Promises April Talks On CBD Regulation

Cannabis stocks were mostly higher Thursday, as investors digested the latest earnings reports from the sector and comments from the head of the U.S. Food and Drug Administration on plans for regulation of CBD.

FDA Commissioner Scott Gottlieb said public meetings will be held sometime in April to hear from relevant parties on how best to regulate CBD derived from hemp, which was legalized in December in the 2018 Farm Bill. The FDA is now responsible for regulating CBD, a non-psychoactive ingredient in cannabis that was not included in hemp legalization because of a lack of research into its longer-term effects on human health.

CBD is widely held to have wellness properties and many cannabis companies are planning to launch food, drinks and cosmetics that contain it, but the FDA has said they cannot do so without its prior approval. Gottlieb told a hearing before a House Appropriations subcommittee that the FDA will form a working group of experts to inform him on regulatory options for the substance, as reported by Marijuana Moment, a website that works with activists, industry representatives and policy makers on trends affecting cannabis.

In case you missed it: Marijuana IPOs in 2019: These companies could be the next hot pot stocks

“I understand Congress wants there to be a pathway for CBD to be available,” he said, although he added that it was “not a straightforward issue.” The FDA has already approved a CBD medication aimed at treating a very severe type of childhood epilepsy, but that was based on traditional clinical trials, a lengthy and expensive process that companies would prefer to avoid.

Gottlieb posited that the FDA could devise a model under which CBD in high concentration would remain a pharmaceutical product, while CBD in a smaller concentration could potentially be added to food or used as a dietary supplement. That separation is needed because “we want to preserve the incentive to study CBD as a pharmaceutical product,” Gottlieb said.

For all of MarketWatch’s coverage of cannabis companies, click here.

The commissioner conceded that the federal ban on cannabis is sending medical cannabis research overseas. The epilepsy drug, epediolex, was developed by U.K. company GW Pharma, which has the ability to use its government license to grow cannabis specifically for drug research and development.

Also on Thursday, the Marijuana Justice Act was reintroduced in Congress, allowing lawmakers to consider policy reform that would end the current federal ban on cannabis and eliminate federal criminal penalties for possession, cultivation, manufacture, import and export of cannabis.

Read: Flow Kana is a weed middleman that expects to make billions as the Sunkist of pot

“Hopefully this legislation will get the serious consideration it deserves,” said Aaron Smith, executive director of the National Cannabis Industry Association, in a statement. “The country is ready and eager to move past prohibition, start addressing the impact it has had on marginalized communities, and explore the economic potential of replacing criminal markets with regulated small businesses.”

Among individual stocks, MedMen Enterprises Inc. shares MMNFF, -5.49%  were down 2.7%, after the company’s second-quarter loss widened from the year-earlier. Revenue rose to $29.9 million from $3 million in the year-ago period. On its earnings call, new Chief Financial Officer Michael Kramer said he had imposed a corporate spending freeze a few weeks ago, a move welcomed by analysts.

Canopy Growth Corp. shares CGC, +3.60% WEED, +4.11%  rose 4.6%. The company said it has signed up a new partner in homemaking guru Martha Stewart, who will act as adviser to develop a new line of CBD-related products. Stewart already has a TV cooking show with cannabis advocate and rapper Snoop Dogg.

Canopy has committed to investing $100 million to $150 million in a hemp industrial park in New York state that aims to be the first such facility in the U.S.

Elsewhere in the sector, Cronos Group Inc. shares CRON, +1.83% CRON, +2.25%  rose 2.6%, Aphria Inc. APHA, +2.17% was up 3.1%, Tilray Inc. TLRY, +2.96%  gained 2.6% and Hexo Corp. HEXO, +0.89%  rose 1.2%.

Aurora Cannabis Inc. ACB, -0.20% ACB, +0.30%  was up 0.9%.

The ETFMG Alternative Harvest ETF MJ, +0.19%  was up 0.3% and the Horizons Marijuana Life Sciences ETF HMMJ, +1.23%  was up 1.4%.

The Dow Jones Industrial Average DJIA, -0.16%  and the S&P 500 SPX, -0.15%  were down about 0.1%.

See now: Marijuana stocks to watch: CannTrust makes its case as a major pot operator

Original Article Source: http://www.marketwatch.com/news/story.asp?guid=%7B6A66DE20-3B73-11E9-83C1-0BC0024172A5%7D&siteid=rss&rss=1

Comments

Post a Comment

Popular posts from this blog

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over  $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...
Post a Comment
Read more

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

NY Dem Chair Warns Against Passing Voter-Supported Marijuana Legalization Bill

The head of New York’s Democratic Party said on Thursday that if the state Senate votes on a marijuana legalization bill, his party’s lawmakers run the risk of alienating voters and losing reelection next year. Jay Jacobs, the state party chairman, claimed that several “far progressive” measures, including cannabis legalization, lack popularity in certain areas across the state such as Long Island and upstate New York. He cautioned lawmakers against putting the issue to a vote, arguing that voters would “throw us out of office.” “It could be the straw that breaks the camel’s back,” he told Newsday. Polling doesn’t support that conclusion, though. According to a March 2019 survey from Quinnipiac, 65 percent of New Yorkers are in favor of allowing adults to legally possess cannabis for personal use. That includes 63 percent of respondents in upstate New York and 65 percent of those living in the suburbs. Sixty-six percent of independents statewide also back ending marijuana prohibit...
Post a Comment
Read more